0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ SUPERNOVA Haidar (DB RCT) -139% 2.39 [0.10-55.8] death 1/41 0/16 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.6 Prophylaxis -139% 2.39 [0.10-55.8] 1/41 0/16 139% higher risk All studies -139% 2.39 [0.10-55.8] 1/41 0/16 139% higher risk 1 AZD5156 COVID-19 study c19early.org June 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.6 Effect extraction pre-specified(most serious outcome) Favors AZD5156 Favors control
Recent:
Haidar.
Jun 18
 Haidar et al., NCT05648110 Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA)
139% higher mortality (p=1). RCT 57 patients showing no significant differences with AZD5156 (sipavibart + cilgavimab).